ScholarIQanswers from OpenAlex & ORCID
Yung‐Jue Bang
ResearcherPublications, citations & collaboration network
Yung‐Jue Bang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yung‐Jue Bang have?
ScholarIQindexed works
Yung‐Jue Bang has 1,071 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yung‐Jue Bang have?
ScholarIQcitation count
Yung‐Jue Bang has 68,433 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yung‐Jue Bang?
ScholarIQh-index
Yung‐Jue Bang has an h-index of 106 in OpenAlex.
What is the i10-index of Yung‐Jue Bang?
ScholarIQi10-index
Yung‐Jue Bang has an i10-index of 476 in OpenAlex.
What is the ORCID of Yung‐Jue Bang?
ScholarIQorcid
The ORCID for Yung‐Jue Bang is on the source record.
What is the OpenAlex record for Yung‐Jue Bang?
ScholarIQopenalex
The OpenAlex for Yung‐Jue Bang is on the source record.
What are the most-cited papers on Yung‐Jue Bang?
ScholarIQmost cited works
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Aaron I. Vinik, Jen‐Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui R. Lu, C. Blanckmeister, Richard C. Chao, Philippe Ruszniewski
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate
KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Gregory J. Riely, Justin F. Gainor, Jeffrey A. Engelman, Geoffrey I. Shapiro, Daniel B. Costa, Sai‐Hong Ignatius Ou, Mohit Butaney, Ravi Salgia, Robert G. Maki, Marileila Varella‐Garcia, Robert C. Doebele, Yung‐Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, A. John Iafrate, D. Ross Camidge